Clinical Trial

A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2020-01-06; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2020-11-20
Trial Details
NCT Number NCT04222062
Lead Sponsor University of Nebraska
Collaborators: Arbor Pharmaceuticals, Inc.
Conditions Brain Tumor - Metastatic
Enrollment 100 participants
Start Date 2020-11-06
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-28